Eun Joo Chung1, Ganesh M Babulal2, Sarah E Monsell3, Nigel J Cairns2, Catherine M Roe2, John C Morris2. 1. Department of Neurology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea. 2. The Charles F. and Joanne Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University School of Medicine, St Louis, Missouri. 3. National Alzheimer's Coordinating Center, University of Washington, Seattle.
Abstract
IMPORTANCE: Lewy bodies are a frequent coexisting pathology in late-onset Alzheimer disease (AD). Previous studies have examined the contribution of Lewy bodies to the clinical phenotype of late-onset AD with variable findings. OBJECTIVE: To determine whether the presence of Lewy body pathology influences the clinical phenotype and progression of symptoms in longitudinally assessed participants with AD. DESIGN, SETTING, AND PARTICIPANTS: Retrospective clinical and pathological cohort study of 531 deceased participants who met the neuropathologic criteria for intermediate or high likelihood of AD according to the National Institute on Aging-Ronald Reagan Institute guidelines for the neuropathologic diagnosis of AD. All participants had a clinical assessment within 2 years of death. The data were obtained from 34 AD centers maintained by the National Alzheimer Coordinating Center and spanned from September 12, 2005, to April 30, 2013. EXPOSURES: Standardized neuropathologic assessment and then brain autopsy after death. MAIN OUTCOMES AND MEASURES: Clinical and neuropsychiatric test scores. RESULTS: The mean (SD) age at death was statistically significantly younger for participants who had AD with Lewy bodies (77.9 [9.5] years) than for participants who had AD without Lewy bodies (80.2 [11.1] years) (P = .01). The mean (SD) age at onset of dementia symptoms was also younger for participants who had AD with Lewy bodies (70.0 [9.9] years) than for participants who had AD without Lewy bodies (72.2 [12.3] years) (P = .03). More men than women had AD with Lewy bodies (P = .01). The frequency of having at least 1 APOE ε4 allele was higher for participants who had AD with Lewy bodies than for participants who had AD without Lewy bodies (P = .03). After adjusting for age, sex, education, frequency of plaques (neuritic and diffuse), and tangle stage, we found that participants who had AD with Lewy bodies had a statistically significantly higher mean (SD) Neuropsychiatric Inventory Questionnaire score (6.59 [1.44] [95% CI, 3.75-9.42] vs 5.49 [1.39] [95% CI, 2.76-8.23]; P = .04) and a statistically significantly higher mean (SD) Unified Parkinson Disease Rating Scale motor score (0.81 [0.18] [95% CI, 0.45-1.17] vs 0.54 [0.18] [95% CI, 0.19-0.88]; P < .001) than did participants who had AD without Lewy bodies. CONCLUSIONS AND RELEVANCE: Participants with both AD and Lewy body pathology have a clinical phenotype that may be distinguished from AD alone. The frequency of Lewy bodies in AD and the association of Lewy bodies with the APOE ε4 allele suggest potential common mechanisms for AD and Lewy body pathologies.
IMPORTANCE: Lewy bodies are a frequent coexisting pathology in late-onset Alzheimer disease (AD). Previous studies have examined the contribution of Lewy bodies to the clinical phenotype of late-onset AD with variable findings. OBJECTIVE: To determine whether the presence of Lewy body pathology influences the clinical phenotype and progression of symptoms in longitudinally assessed participants with AD. DESIGN, SETTING, AND PARTICIPANTS: Retrospective clinical and pathological cohort study of 531 deceased participants who met the neuropathologic criteria for intermediate or high likelihood of AD according to the National Institute on Aging-Ronald Reagan Institute guidelines for the neuropathologic diagnosis of AD. All participants had a clinical assessment within 2 years of death. The data were obtained from 34 AD centers maintained by the National Alzheimer Coordinating Center and spanned from September 12, 2005, to April 30, 2013. EXPOSURES: Standardized neuropathologic assessment and then brain autopsy after death. MAIN OUTCOMES AND MEASURES: Clinical and neuropsychiatric test scores. RESULTS: The mean (SD) age at death was statistically significantly younger for participants who had AD with Lewy bodies (77.9 [9.5] years) than for participants who had AD without Lewy bodies (80.2 [11.1] years) (P = .01). The mean (SD) age at onset of dementia symptoms was also younger for participants who had AD with Lewy bodies (70.0 [9.9] years) than for participants who had AD without Lewy bodies (72.2 [12.3] years) (P = .03). More men than women had AD with Lewy bodies (P = .01). The frequency of having at least 1 APOE ε4 allele was higher for participants who had AD with Lewy bodies than for participants who had AD without Lewy bodies (P = .03). After adjusting for age, sex, education, frequency of plaques (neuritic and diffuse), and tangle stage, we found that participants who had AD with Lewy bodies had a statistically significantly higher mean (SD) Neuropsychiatric Inventory Questionnaire score (6.59 [1.44] [95% CI, 3.75-9.42] vs 5.49 [1.39] [95% CI, 2.76-8.23]; P = .04) and a statistically significantly higher mean (SD) Unified Parkinson Disease Rating Scale motor score (0.81 [0.18] [95% CI, 0.45-1.17] vs 0.54 [0.18] [95% CI, 0.19-0.88]; P < .001) than did participants who had AD without Lewy bodies. CONCLUSIONS AND RELEVANCE: Participants with both AD and Lewy body pathology have a clinical phenotype that may be distinguished from AD alone. The frequency of Lewy bodies in AD and the association of Lewy bodies with the APOE ε4 allele suggest potential common mechanisms for AD and Lewy body pathologies.
Authors: Y Stern; D Jacobs; J Goldman; E Gomez-Tortosa; B T Hyman; Y Liu; J Troncoso; K Marder; M X Tang; J Brandt; M Albert Journal: Arch Neurol Date: 2001-03
Authors: D I Kaufer; J L Cummings; P Ketchel; V Smith; A MacMillan; T Shelley; O L Lopez; S T DeKosky Journal: J Neuropsychiatry Clin Neurosci Date: 2000 Impact factor: 2.198
Authors: Michael Serby; Adam M Brickman; Vahram Haroutunian; Dushyant P Purohit; Deborah Marin; Melinda Lantz; Richard C Mohs; Kenneth L Davis Journal: Am J Geriatr Psychiatry Date: 2003 May-Jun Impact factor: 4.105
Authors: Melinda C Power; Elizabeth Mormino; Anja Soldan; Bryan D James; Lei Yu; Nicole M Armstrong; Katherine J Bangen; Lisa Delano-Wood; Melissa Lamar; Yen Ying Lim; Kelly Nudelman; Laura Zahodne; Alden L Gross; Dan Mungas; Keith F Widaman; Julie Schneider Journal: Ann Neurol Date: 2018-06-26 Impact factor: 10.422
Authors: Koji Kasanuki; Owen A Ross; Michael A DeTure; Ronald L Walton; Monica Sanchez-Contreras; Shunsuke Koga; Melissa E Murray; Rosa Rademakers; Dennis W Dickson Journal: Mov Disord Date: 2018-01-11 Impact factor: 10.338
Authors: Rizwan S Akhtar; Joseph P Licata; Kelvin C Luk; Leslie M Shaw; John Q Trojanowski; Virginia M-Y Lee Journal: J Neurochem Date: 2018-06-10 Impact factor: 5.372
Authors: Jessica Tulloch; Lesley Leong; Sunny Chen; C Dirk Keene; Steven P Millard; Andrew Shutes-David; Oscar L Lopez; Julia Kofler; Jeffrey A Kaye; Randy Woltjer; Peter T Nelson; Janna H Neltner; Gregory A Jicha; Douglas Galasko; Eliezer Masliah; James B Leverenz; Chang-En Yu; Debby Tsuang Journal: Alzheimers Dement Date: 2018-03-12 Impact factor: 21.566